Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 29

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 16
Chunk 29
---
 $— $1,504,158 There were no transfers between Level 1 and Level 2 and we had no financial assets or liabilities that were classified as Level 3 at any point during the year ended December 31, 2024.

Note 4. Marketable Securities

Marketable securities at December 31, 2024 consisted of the following:(In thousands)AmortizedCostUnrealizedGainsUnrealizedLossesFairValueCurrent:Certificates of deposit$10,374 $11 $— $10,385 U.S. Treasuries173,465 153 (27)173,591 Government securities167,970 103 (75)167,998 Corporate debt securities465,427 321 (259)465,489 Total Current817,236 588 (361)817,463 Non-current:U.S. Treasuries107,725 106 (303)107,528 Government securities112,175 3 (469)111,709 Corporate debt securities420,166 181 (1,263)419,084 Total Non-current640,066 290 (2,035)638,321 Total marketable securities$1,457,302 $878 $(2,396)$1,455,784 

F-16

Marketable securities at December 31, 2023 consisted of the following:(In thousands)AmortizedCostUnrealizedGainsUnrealizedLossesFairValueCurrent:U.S. Treasuries$30,876 $— $(56)$30,820 Government securities247,460 194 (695)246,959 Corporate debt securities411,045 874 (975)410,944 Total Current689,381 1,068 (1,726)688,723 Non-current:U.S. Treasuries4,802 30 — 4,832 Government securities9,986 75 — 10,061 Corporate debt securities14,430 112 — 14,542 Total Non-current29,218 217 — 29,435 Total marketable securities$718,599 $1,285 $(1,726)$718,158 There were no material realized gains or losses on marketable securities for the years ended December 31, 2024 and 2023.At December 31